Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Research and Innovation Action · Running

ENCANTO ENgineered CArtilage from Nose for the Treatment of Osteoarthritis (ENCANTO)

Coordinator
Fondazione Policlinico Universitario Campus Bio Medico, Italy
Runs
1 January 2024 to 31 December 2029
Status
Running
EU funding
€8.4m
Total cost
€8.4m
Partners
20 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101137315

What the project is doing

In the project's own words, from its summary on CORDIS.

Knee osteoarthritis (OA) is one of the most common causes of pain and disability, affecting over 500 million people worldwide. The tremendous socio-economic burden caused by OA is expected to further increase due to rising life expectancy and obesity. Current therapeutic approaches are limited to pain management or knee arthroplasty, but no disease-modifying or regenerative treatment is available. ENCANTO will address this major unmet clinical need by clinically introducing a combined ATMP for the biological reconstruction of the degenerated joint facet in patellofemoral OA (PFOA).

This tissue-engineered cartilage (N-TEC), based on autologous nasal chondrocytes and a collagen membrane, was previously successfully used for focal cartilage lesions. The central part of ENCANTO is an international, blinded, multicenter, prospective randomized controlled phase II trial to clinically assess the efficacy of N-TEC for the treatment of PFOA. Patients’ samples will be analyzed to retrospectively identify PFOA molecular endotypes and associated biomarker signatures with the most successful clinical outcome after N-TEC implantation, to predictively select responders to therapy.

To achieve these aims ENCANTO brings together tissue engineers with practice in ATMPs, knee surgery and rehabilitation specialists, research institutes experienced in regulatory affairs, health economics and ATMP development, excellent scientists involved in the assessment of OA endotypes, and patients’ representatives. SMEs from the consortium will develop a road map towards commercial exploitation, including centralized marketing authorization.

After demonstrating efficacy for PFOA, N-TEC will be considered for other forms of OA in different joints. ENCANTO will thus introduce the first disease-modifying therapy for cartilage degeneration, enable mobility and social gain for a large patient group and play a pivotal role in strengthening Europe's position in delivering regenerative medicine solutions.

Topics

Who is involved

OrganisationCityCountryRole
Fondazione Policlinico Universitario Campus Bio MedicoRomaItalyCoordinator
Medizinische Universitaet WienWienAustriaParticipant
Ortopadisches Spital Speising GmbHWienAustriaParticipant
Universitat BaselBaselSwitzerlandAssociatedpartner
Universitatsspital BaselBaselSwitzerlandAssociatedpartner
crossklinik AGBaselSwitzerlandAssociatedpartner
Evangelisches Waldkrankenhaus Spandau Krankenhausbetriebs GgmbhBerlinGermanyParticipant
Julius-Maximilians-Universitat WurzburgWuerzburgGermanyParticipant
Promove-Biotec GmbHNurnbergGermanyParticipant
Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-UniversitatWurzburgGermanyParticipant
Theracell Proigmenes Viotechnologikes Efarmoges Monoprosopi Anonymi EtaireiaN. KifisiaGreeceParticipant
Oulun YliopistoOuluFinlandParticipant
Klinicka Bolnica Sveti DuhZagrebCroatiaParticipant
Videoreha Drustvo S Ogranicenom Odgovornoscu Za UslugeZagrebCroatiaParticipant
Ospedale Galeazzi SpAMilanoItalyThird party
Universita Degli Studi Di MilanoMilanoItalyParticipant
Academisch Ziekenhuis MaastrichtMaastrichtNetherlandsParticipant
Universiteit MaastrichtMaastrichtNetherlandsParticipant
Szpital Specjalistyczny Im. Stefana Zeromskiego Samodzielny Publiczny Zaklad Opieki Zdrowotnej W KrakowieKrakowPolandParticipant
Vastra GotalandsregionenVanersborgSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI